SHR-1701 in Patients With Recurrent/Metastatic Scchn
This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN
Squamous Cell Carcinoma of Head and Neck
DRUG: SHR-1701
Objective Response Rate (ORR) per RECIST 1.1, ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least 30% decrease in the sum of diameters of target lesions) per RECIST 1.1., up to 2 years
DOR, Duration of response, 24 months|DCR, Disease Control Rate, 24 months|PFS, Progression free survival, 24 months|OS, Overall Survival, 24 months|AEs, Incidence and severity of adverse events, 24 months
This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN